Ojjaara (momelotinib)

pCPA File Number: 22982
Negotiation Status:
Active Negotiation
Indication(s):
For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia.
Sponsor/Manufacturer:
GlaxoSmithKline Inc.
CDA-AMC Project Number:
PC0355-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable